SGR-2921

A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
50 patients (estimated)
Sponsors
Schrödinger, Inc.
Tags
CDC7 Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1784
NCT Identifier
NCT05961839

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.